Cirius Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH.
View Top Employees from Cirius Therapeutics| Website | http://www.ciriustx.com |
| Revenue | $2 million |
| Funding | $56.4 million |
| Employees | 1 (1 on RocketReach) |
| Founded | 2015 |
| Address | 12651 High Bluff Dr, Ste 150, San Diego, California 92130, US |
| Phone | (858) 333-6274 |
| Industry | Biopharma, Biotechnology, Health Care, Science and Engineering, Medical Device, Pharmaceutical |
| Competitors | Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Metacrine, Inc., Nimbus Therapeutics, Trana Discovery, Inc. |
| SIC | SIC Code 21 Companies, SIC Code 20 Companies |
| NAICS | NAICS Code 33 Companies, NAICS Code 31 Companies, NAICS Code 312 Companies, NAICS Code 3122 Companies |
Looking for a particular Cirius Therapeutics employee's phone or email?
Cirius Therapeutics Questions
The Cirius Therapeutics annual revenue was $2 million in 2023.
1 people are employed at Cirius Therapeutics.
Cirius Therapeutics is based in San Diego, California.
The NAICS codes for Cirius Therapeutics are [33, 31, 312, 3122].
The SIC codes for Cirius Therapeutics are [21, 20].
